ARCHIVES

Tamoxifen: No Mortality Benefit For Most “High Risk” Women

This article is from The Cancer Letter archive.

Vol. 29 No. 9 | September 29, 2006

Download PDF Visit The Full Archive

Related Articles

Impeding Reagan Budget Cuts Feared By Cancer Program Advocates; DeVita Asks Parity With NIH

February 13, 1981

In Brief: Chance for Rauscher Pay Increase Bill Seems Diminishing, But Schmidt Remains Confident

April 30, 1976

Femara Better Suppressor Of Estrogen, Study Finds

February 22, 2002

FDA Approves Large-Volume Processor For Cytyc’s ThinPrep Pap Test Samples.

June 30, 2000

Lombardi Center Officials Say New Partnership To Provide For Expansion In Services, Patients.

February 23, 2001

Varmus: Plan Would Give Trials A Strong Scientific Base

December 17, 2010